Symbol="ITOS"
AssetType="Common Stock"
Name="Iteos TherapeuticsÂ Inc"
Description="Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of immuno-oncology therapies for patients. The company is headquartered in Cambridge, Massachusetts."
CIK="1808865"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="139 MAIN STREET, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="461586000"
EBITDA="-63267000"
PERatio="None"
PEGRatio="None"
BookValue="17.43"
DividendPerShare="0"
DividendYield="0"
EPS="-0.76"
RevenuePerShareTTM="2.411"
ProfitMargin="-0.33"
OperatingMarginTTM="-0.746"
ReturnOnAssetsTTM="-0.0528"
ReturnOnEquityTTM="-0.0451"
RevenueTTM="85987000"
GrossProfitTTM="267630000"
DilutedEPSTTM="-0.76"
QuarterlyEarningsGrowthYOY="-0.886"
QuarterlyRevenueGrowthYOY="-0.917"
AnalystTargetPrice="39.75"
TrailingPE="-"
ForwardPE="12.56"
PriceToSalesRatioTTM="1.681"
PriceToBookRatio="1.187"
EVToRevenue="0.0111"
EVToEBITDA="0.0154"
Beta="1.167"
num_52WeekHigh="24.39"
num_52WeekLow="11.34"
num_50DayMovingAverage="13.29"
num_200DayMovingAverage="16.26"
SharesOutstanding="35781900"
DividendDate="None"
ExDividendDate="None"
symbol="ITOS"
open="13.68"
high="13.83"
low="12.81"
price="12.90"
volume="379660.00"
latest_trading_day="2023-08-25"
previous_close="13.76"
change="-0.86"
change_percent="-6.2500%"
aroon_positive_momentum_days="21"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="High Volatility / Hold Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="TRUE"
Aroon_momentum="21"
Volume_recent_avg="364379"
Change_recent_avg="-0.06"
Delta_recent_avg="0.71"
Variance_recent_avg="0.35"
Change_ratio_recent_avg="-0.53"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="positive"
Aroon_change="TRUE"
Aroon_momentum_positive="21"
Aroon_momentum_negative="79"
image_negative_thumbnail_id_1="1110"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0143.jpeg"
image_negative_thumbnail_id_2="166"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0010.jpeg"
image_neutral_thumbnail_id_1="565"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0034.jpeg"
image_neutral_thumbnail_id_2="566"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0033.jpeg"
image_positive_thumbnail_id_1="629"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0079.jpeg"
image_positive_thumbnail_id_2="649"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0059.jpeg"
image_professor_thumbnail_id_1="1196"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
image_professor_thumbnail_id_2="1201"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0035.jpeg"
